-
1
-
-
0033345349
-
A survey of the polycystic ovary syndrome in the Greek island of Lesbos: Hormonal and metabolic profile
-
Diamanti-Kandarakis E, Kouli CR, Bergiele AT, et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 1999, 84: 4006-11.
-
(1999)
J Clin Endocrinol Metab
, vol.84
, pp. 4006-4011
-
-
Diamanti-Kandarakis, E.1
Kouli, C.R.2
Bergiele, A.T.3
-
2
-
-
2942642477
-
The prevalence and features of the polycystic ovary syndrome in an unselected population
-
Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004, 89: 2745-9.
-
(2004)
J Clin Endocrinol Metab
, vol.89
, pp. 2745-2749
-
-
Azziz, R.1
Woods, K.S.2
Reyna, R.3
Key, T.J.4
Knochenhauer, E.S.5
Yildiz, B.O.6
-
3
-
-
33751526500
-
Androgen Excess Society. Positions statement: Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline
-
Azziz R, Carmina E, Dewailly D, et al. Androgen Excess Society. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 2006, 91: 4237-45.
-
(2006)
J Clin Endocrinol Metab
, vol.91
, pp. 4237-4245
-
-
Azziz, R.1
Carmina, E.2
Dewailly, D.3
-
5
-
-
0034979463
-
Concerted transcriptional activation of the low density lipoprotein receptor gene by insulin and luteinizing hormone in cultured porcine granulosa-luteal cells: Possible convergence of protein kinase a, phosphatidylinositol 3-kinase, and mitogen-activated protein kinase signaling pathways
-
Sekar N, Veldhuis JD. Concerted transcriptional activation of the low density lipoprotein receptor gene by insulin and luteinizing hormone in cultured porcine granulosa-luteal cells: possible convergence of protein kinase a, phosphatidylinositol 3-kinase, and mitogen-activated protein kinase signaling pathways. Endocrinology 2001, 142: 2921-8.
-
(2001)
Endocrinology
, vol.142
, pp. 2921-2928
-
-
Sekar, N.1
Veldhuis, J.D.2
-
6
-
-
0027200314
-
Sites of inhibition of steroidogenesis by activation of protein kirrase-C in swine ovarian (granulosa) cells
-
Flores JA, Garmey JC, Nestler JE, Veldhuis JD. Sites of inhibition of steroidogenesis by activation of protein kirrase-C in swine ovarian (granulosa) cells. Endocrinology 1993, 132: 1983-90.
-
(1993)
Endocrinology
, vol.132
, pp. 1983-1990
-
-
Flores, J.A.1
Garmey, J.C.2
Nestler, J.E.3
Veldhuis, J.D.4
-
7
-
-
0030027986
-
The effect of insulin and insulin-like growth factors on the expression of steroidogenic enzymes in a human ovarian thecal-like tumor cell model
-
McGee EA, Sawetawan C, Bird I, Rainey WE, Carr B. The effect of insulin and insulin-like growth factors on the expression of steroidogenic enzymes in a human ovarian thecal-like tumor cell model. Fertil Steril 1996, 65: 87-93.
-
(1996)
Fertil Steril
, vol.65
, pp. 87-93
-
-
McGee, E.A.1
Sawetawan, C.2
Bird, I.3
Rainey, W.E.4
Carr, B.5
-
8
-
-
0034463967
-
Interactive stimulation by luteinizing hormone and insulin of the steroidogenic acute regulatory (StAR) protein and 17alpha-hydroxylase/17,20-lyase (CYP17) genes in porcine theca cells
-
Zhang G, Garmey JC, Veldhuis JD. Interactive stimulation by luteinizing hormone and insulin of the steroidogenic acute regulatory (StAR) protein and 17alpha-hydroxylase/17,20-lyase (CYP17) genes in porcine theca cells. Endocrinology 2000, 141: 2735-42.
-
(2000)
Endocrinology
, vol.141
, pp. 2735-2742
-
-
Zhang, G.1
Garmey, J.C.2
Veldhuis, J.D.3
-
9
-
-
33746220070
-
Molecular mechanisms of insulin resistance in polycystic ovary syndrome
-
Diamanti-Kandarakis E, Papavassiliou AG. Molecular mechanisms of insulin resistance in polycystic ovary syndrome. Trends Mol Med 2006, 12: 324-32.
-
(2006)
Trends Mol Med
, vol.12
, pp. 324-332
-
-
Diamanti-Kandarakis, E.1
Papavassiliou, A.G.2
-
10
-
-
34548426625
-
Polycystic ovarian syndrome: The commonest cause of hyperandrogenemia in women as a risk factor for metabolic syndrome
-
Diamanti-Kandarakis E, Christakou C, Kandarakis H. Polycystic ovarian syndrome: the commonest cause of hyperandrogenemia in women as a risk factor for metabolic syndrome. Minerva Endocrinol 2007, 32: 35-47.
-
(2007)
Minerva Endocrinol
, vol.32
, pp. 35-47
-
-
Diamanti-Kandarakis, E.1
Christakou, C.2
Kandarakis, H.3
-
11
-
-
17444445125
-
-
Rizza RA. Androgen effect on insulin action and glucose metabolism. Mayo Clin Proc 2000, 75 8Suppl: S61-4.
-
Rizza RA. Androgen effect on insulin action and glucose metabolism. Mayo Clin Proc 2000, 75 8Suppl): S61-4.
-
-
-
-
12
-
-
0033767890
-
Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women
-
Talbott EO, Guzick DS, Sutton-Tyrrell K, et al. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol 2000, 20: 2414-21.
-
(2000)
Arterioscler Thromb Vasc Biol
, vol.20
, pp. 2414-2421
-
-
Talbott, E.O.1
Guzick, D.S.2
Sutton-Tyrrell, K.3
-
13
-
-
24344448639
-
Predictors of endothelial dysfunction in young women with polycystic ovary syndrome
-
Kravariti M, Naka KK, Kalantaridou SN, et al. Predictors of endothelial dysfunction in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005, 90: 5088-95.
-
(2005)
J Clin Endocrinol Metab
, vol.90
, pp. 5088-5095
-
-
Kravariti, M.1
Naka, K.K.2
Kalantaridou, S.N.3
-
14
-
-
36849023426
-
Young Obese Women with Polycystic Ovary Syndrome have Evidence of Early Coronary Atherosclerosis
-
Shroff R, Kirschner A, Maifeld M, Van Beek EJ, Jagasia D, Dokras A. Young Obese Women with Polycystic Ovary Syndrome have Evidence of Early Coronary Atherosclerosis. J Clin Endocrinol Metab 2007, 92: 4609-14.
-
(2007)
J Clin Endocrinol Metab
, vol.92
, pp. 4609-4614
-
-
Shroff, R.1
Kirschner, A.2
Maifeld, M.3
Van Beek, E.J.4
Jagasia, D.5
Dokras, A.6
-
15
-
-
0038031022
-
A modern medical quandary: Polycystic ovary syndrome, insulin resistance, and oral contraceptive pills
-
Diamanti-Kandarakis E, Baillargeon JP, Iuorno MJ, Jakubowicz DJ, Nestler JE, A modern medical quandary: polycystic ovary syndrome, insulin resistance, and oral contraceptive pills. J Clin Endocrinol Metab 2003, 88: 1927-32.
-
(2003)
J Clin Endocrinol Metab
, vol.88
, pp. 1927-1932
-
-
Diamanti-Kandarakis, E.1
Baillargeon, J.P.2
Iuorno, M.J.3
Jakubowicz, D.J.4
Nestler, J.E.5
-
16
-
-
34548273096
-
Pathophysiology and types of dyslipidemia in PCOS
-
Diamanti-Kandarakis E, Papavassiliou AG, Kandarakis SA, Chrousos GP. Pathophysiology and types of dyslipidemia in PCOS. Trends Endocrinol Metab 2007, 18: 280-5.
-
(2007)
Trends Endocrinol Metab
, vol.18
, pp. 280-285
-
-
Diamanti-Kandarakis, E.1
Papavassiliou, A.G.2
Kandarakis, S.A.3
Chrousos, G.P.4
-
17
-
-
0035702475
-
Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome
-
Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med 2001, 111: 607-13.
-
(2001)
Am J Med
, vol.111
, pp. 607-613
-
-
Legro, R.S.1
Kunselman, A.R.2
Dunaif, A.3
-
18
-
-
33846086155
-
Atherogenic lipoprotein phenotype and low-density lipoproteins size and sub-classes in women with polycystic ovary syndrome
-
Berneis K, Rizzo M, Lazzarini V, Fruzzetti F, Carmina E. Atherogenic lipoprotein phenotype and low-density lipoproteins size and sub-classes in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2007, 92:186-9.
-
(2007)
J Clin Endocrinol Metab
, vol.92
, pp. 186-189
-
-
Berneis, K.1
Rizzo, M.2
Lazzarini, V.3
Fruzzetti, F.4
Carmina, E.5
-
19
-
-
33644558330
-
Cardiovascular disease in the polycystic ovary syndrome: New insights and perspectives
-
Cussons AJ, Stuckey BG, Watts GF. Cardiovascular disease in the polycystic ovary syndrome: new insights and perspectives. Atherosclerosis 2006, 185: 227-39.
-
(2006)
Atherosclerosis
, vol.185
, pp. 227-239
-
-
Cussons, A.J.1
Stuckey, B.G.2
Watts, G.F.3
-
20
-
-
21244477051
-
Pa ao lu H. Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome
-
Yilmaz M, Biri A, Bukan N, Karakoç A, Sancak B, Törüner F, Pa ao lu H. Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome. Gynecol Endocrinol 2005, 20: 258-63.
-
(2005)
Gynecol Endocrinol
, vol.20
, pp. 258-263
-
-
Yilmaz, M.1
Biri, A.2
Bukan, N.3
Karakoç, A.4
Sancak, B.5
Törüner, F.6
-
21
-
-
33748708041
-
Inflammatory and endothelial markers in women with polycystic ovary syndrome
-
Diamanti-Kandarakis E, Alexandraki K, Piperi C, et al. Inflammatory and endothelial markers in women with polycystic ovary syndrome. Eur J Clin Invest 2006, 36: 691-7.
-
(2006)
Eur J Clin Invest
, vol.36
, pp. 691-697
-
-
Diamanti-Kandarakis, E.1
Alexandraki, K.2
Piperi, C.3
-
22
-
-
0037326227
-
Homocysteine levels and C677T polymorphism of methylenetetrahydrofolate reductase in women with polycystic ovary syndrome
-
Orio F Jr, Palomba S, Di Biase S, et al. Homocysteine levels and C677T polymorphism of methylenetetrahydrofolate reductase in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003, 88: 673-9.
-
(2003)
J Clin Endocrinol Metab
, vol.88
, pp. 673-679
-
-
Orio Jr, F.1
Palomba, S.2
Di Biase, S.3
-
23
-
-
2442434415
-
Increased C-reactive protein levels in the polycystic ovary syndrome: A marker of cardiovascular disease
-
Boulman N, Levy Y, Leiba R, et al. Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. J Clin Endocrinol Metab 2004, 89: 2160-5.
-
(2004)
J Clin Endocrinol Metab
, vol.89
, pp. 2160-2165
-
-
Boulman, N.1
Levy, Y.2
Leiba, R.3
-
25
-
-
34447543075
-
Nitric oxide and fibrinogen in polycystic ovary syndrome: Associations with insulin resistance and obesity
-
Nácul AP, Andrade CD, Schwarz P, de Bittencourt PI Jr, Spritzer PM. Nitric oxide and fibrinogen in polycystic ovary syndrome: associations with insulin resistance and obesity. Eur J Obstet Gynecol Reprod Biol 2007, 133: 191-6.
-
(2007)
Eur J Obstet Gynecol Reprod Biol
, vol.133
, pp. 191-196
-
-
Nácul, A.P.1
Andrade, C.D.2
Schwarz, P.3
de Bittencourt Jr, P.I.4
Spritzer, P.M.5
-
26
-
-
38149040839
-
Asymmetric dimethylarginine, inflammatory and metabolic parameters in women with polycystic ovary syndrome before and after metformin treatment
-
Heutling D, Schulz H, Nickel I, et al. Asymmetric dimethylarginine, inflammatory and metabolic parameters in women with polycystic ovary syndrome before and after metformin treatment. J Clin Endocrinol Metab 2008, 93: 82-90.
-
(2008)
J Clin Endocrinol Metab
, vol.93
, pp. 82-90
-
-
Heutling, D.1
Schulz, H.2
Nickel, I.3
-
27
-
-
38349111105
-
The administration of estrogens, combined with anti-androgens, has beneficial effects on the hormonal features and asymmetric dimethyl-arginine levels, in women with the polycystic ovary syndrome
-
Charitidou C, Farmakiotis D, Zournatzi V, et al. The administration of estrogens, combined with anti-androgens, has beneficial effects on the hormonal features and asymmetric dimethyl-arginine levels, in women with the polycystic ovary syndrome. Atherosclerosis 2008, 196: 958-65.
-
(2008)
Atherosclerosis
, vol.196
, pp. 958-965
-
-
Charitidou, C.1
Farmakiotis, D.2
Zournatzi, V.3
-
28
-
-
8844247151
-
The plasminogen activator system in young and lean women with polycystic ovary syndrome
-
Tarkun I, Cantürk Z, Arslan BC, Türemen E, Tarkun P. The plasminogen activator system in young and lean women with polycystic ovary syndrome. Endocr J 2004, 51: 467-72.
-
(2004)
Endocr J
, vol.51
, pp. 467-472
-
-
Tarkun, I.1
Cantürk, Z.2
Arslan, B.C.3
Türemen, E.4
Tarkun, P.5
-
29
-
-
0036323992
-
A specific elevation in tissue plasminogen activator antigen in women with polycystic ovarian syndrome
-
Kelly CJ, Lyall H, Petrie JR, et al. A specific elevation in tissue plasminogen activator antigen in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2002, 87: 3287-90.
-
(2002)
J Clin Endocrinol Metab
, vol.87
, pp. 3287-3290
-
-
Kelly, C.J.1
Lyall, H.2
Petrie, J.R.3
-
30
-
-
3242720491
-
The prevalence of 4G5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene in polycystic ovarian syndrome and its association with plasma PAI-1 levels
-
Diamanti-Kandarakis E, Palioniko G, Alexandraki K, Bergiele A, Koutsouba T, Bartzis M. The prevalence of 4G5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene in polycystic ovarian syndrome and its association with plasma PAI-1 levels. Eur J Endocrinol 2004, 150: 793-8.
-
(2004)
Eur J Endocrinol
, vol.150
, pp. 793-798
-
-
Diamanti-Kandarakis, E.1
Palioniko, G.2
Alexandraki, K.3
Bergiele, A.4
Koutsouba, T.5
Bartzis, M.6
-
31
-
-
8744223271
-
Is plasminogen activator inhibitor-1 a cardiovascular risk factor in young women with polycystic ovary syndrome
-
Orio F Jr, Palomba S, Cascella T, et al. Is plasminogen activator inhibitor-1 a cardiovascular risk factor in young women with polycystic ovary syndrome. Reprod Biomed Online 2004, 9: 505-10.
-
(2004)
Reprod Biomed Online
, vol.9
, pp. 505-510
-
-
Orio Jr, F.1
Palomba, S.2
Cascella, T.3
-
32
-
-
0002443834
-
Raised plasminogen activator inhibitor-1 (PAI-1) is not an independent risk factor in the polycystic ovary syndrome (PCOS)
-
Atiomo WU, Fox R, Condon JE, et al. Raised plasminogen activator inhibitor-1 (PAI-1) is not an independent risk factor in the polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf) 2000, 52: 487-92.
-
(2000)
Clin Endocrinol (Oxf)
, vol.52
, pp. 487-492
-
-
Atiomo, W.U.1
Fox, R.2
Condon, J.E.3
-
33
-
-
34548319286
-
Transgenic overexpression of plasminogen activator inhibitor-1 promotes the development of polycystic ovarian changes in female mice
-
Devin JK, Johnson JE, Eren M, et al. Transgenic overexpression of plasminogen activator inhibitor-1 promotes the development of polycystic ovarian changes in female mice. J Mol Endocrinol 2007, 39: 9-16.
-
(2007)
J Mol Endocrinol
, vol.39
, pp. 9-16
-
-
Devin, J.K.1
Johnson, J.E.2
Eren, M.3
-
34
-
-
0034883317
-
Oxidative stress in polycystic ovary syndrome and its contribution to the risk of cardiovascular disease
-
Sabuncu T, Vural H, Harma M, Harma M. Oxidative stress in polycystic ovary syndrome and its contribution to the risk of cardiovascular disease. Clin Biochem 2001, 34: 407-13.
-
(2001)
Clin Biochem
, vol.34
, pp. 407-413
-
-
Sabuncu, T.1
Vural, H.2
Harma, M.3
Harma, M.4
-
35
-
-
0037707406
-
Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome may contribute to the risk of cardiovascular disease
-
Fenkci V, Fenkci S, Yilmazer M, Serteser M. Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome may contribute to the risk of cardiovascular disease. Fertil Steril 2003, 80: 123-7.
-
(2003)
Fertil Steril
, vol.80
, pp. 123-127
-
-
Fenkci, V.1
Fenkci, S.2
Yilmazer, M.3
Serteser, M.4
-
36
-
-
35148846863
-
Single oral challenge by advanced glycation end products acutely impairs endothelial function in diabetic and nondiabetic subjects
-
Uribarri J, Stirban A, Sander D, et al. Single oral challenge by advanced glycation end products acutely impairs endothelial function in diabetic and nondiabetic subjects. Diabetes Care 2007, 30: 2579-82.
-
(2007)
Diabetes Care
, vol.30
, pp. 2579-2582
-
-
Uribarri, J.1
Stirban, A.2
Sander, D.3
-
37
-
-
12944319290
-
Increased levels of serum advanced glycation end-products in women with polycystic ovary syndrome
-
Diamanti-Kandarakis E, Piperi C, Kalofoutis A. Increased levels of serum advanced glycation end-products in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2005, 62: 37-43.
-
(2005)
Clin Endocrinol (Oxf)
, vol.62
, pp. 37-43
-
-
Diamanti-Kandarakis, E.1
Piperi, C.2
Kalofoutis, A.3
-
38
-
-
36849093893
-
Accumulation of dietary glycotoxins in the reproductive system of normal female rats
-
Diamanti-Kandarakis E, Piperi C, Korkolopoulou P, et al. Accumulation of dietary glycotoxins in the reproductive system of normal female rats. J Mol Med 2007, 85: 1413-20.
-
(2007)
J Mol Med
, vol.85
, pp. 1413-1420
-
-
Diamanti-Kandarakis, E.1
Piperi, C.2
Korkolopoulou, P.3
-
39
-
-
34249937629
-
Immunohistochemical localization of advanced glycation end-products (AGEs) and their receptor (RAGE) in polycystic and normal ovaries
-
Diamanti-Kandarakis E, Piperi C, Patsouris E, et al. Immunohistochemical localization of advanced glycation end-products (AGEs) and their receptor (RAGE) in polycystic and normal ovaries. Histochem Cell Biol 2007, 127: 581-9.
-
(2007)
Histochem Cell Biol
, vol.127
, pp. 581-589
-
-
Diamanti-Kandarakis, E.1
Piperi, C.2
Patsouris, E.3
-
40
-
-
1842864234
-
Plasma adiponectin levels and risk of myocardial infarction in men
-
Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004, 291: 1730-37.
-
(2004)
JAMA
, vol.291
, pp. 1730-1737
-
-
Pischon, T.1
Girman, C.J.2
Hotamisligil, G.S.3
Rifai, N.4
Hu, F.B.5
Rimm, E.B.6
-
41
-
-
33750325774
-
Adiponectin is a candidate marker of metabolic syndrome in obese children and adolescents
-
Gilardini L, McTernan PG, Girola A, et al. Adiponectin is a candidate marker of metabolic syndrome in obese children and adolescents. Atherosclerosis 2006, 189: 401-7.
-
(2006)
Atherosclerosis
, vol.189
, pp. 401-407
-
-
Gilardini, L.1
McTernan, P.G.2
Girola, A.3
-
42
-
-
0043265072
-
Serum adiponectin levels in women with polycystic ovary syndrome
-
Panidis D, Kourtis A, Farmakiotis D, Mouslech T, Rousso D, Koliakos G. Serum adiponectin levels in women with polycystic ovary syndrome. Hum Reprod 2003, 18: 1790-6.
-
(2003)
Hum Reprod
, vol.18
, pp. 1790-1796
-
-
Panidis, D.1
Kourtis, A.2
Farmakiotis, D.3
Mouslech, T.4
Rousso, D.5
Koliakos, G.6
-
43
-
-
10844279820
-
Adiponectin is independently associated with insulin sensitivity in women with polycystic ovary syndrome
-
Spranger J, Möhlig M, Wegewitz U, et al. Adiponectin is independently associated with insulin sensitivity in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2004, 61: 738-46.
-
(2004)
Clin Endocrinol (Oxf)
, vol.61
, pp. 738-746
-
-
Spranger, J.1
Möhlig, M.2
Wegewitz, U.3
-
44
-
-
40349085646
-
Subcutaneous and omental fat expression of adiponectin and leptin in women with polycystic ovary syndrome
-
Carmina E, Chu MC, Moran C, et al. Subcutaneous and omental fat expression of adiponectin and leptin in women with polycystic ovary syndrome. Fertil Steril 2008, 89: 642-8.
-
(2008)
Fertil Steril
, vol.89
, pp. 642-648
-
-
Carmina, E.1
Chu, M.C.2
Moran, C.3
-
45
-
-
2942687834
-
Adiponectin: A novel adipokine linking adipocytes and vascular function
-
Goldstein BJ, Scalia R. Adiponectin: A novel adipokine linking adipocytes and vascular function. J Clin Endocrinol Metab 2004, 89: 2563-8.
-
(2004)
J Clin Endocrinol Metab
, vol.89
, pp. 2563-2568
-
-
Goldstein, B.J.1
Scalia, R.2
-
46
-
-
36849025505
-
Early Metabolic derangements in daughters of women with polycystic ovary syndrome
-
Sir-Petermann T, Maliqueo M, Codner E, et al. Early Metabolic derangements in daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2007, 92: 4637-42.
-
(2007)
J Clin Endocrinol Metab
, vol.92
, pp. 4637-4642
-
-
Sir-Petermann, T.1
Maliqueo, M.2
Codner, E.3
-
47
-
-
34548315745
-
The circulating PBEF/ NAMPT/visfatin level is associated with a beneficial blood lipid profile
-
Wang P, van Greevenbroek MM, Bouwman FG, et al. The circulating PBEF/ NAMPT/visfatin level is associated with a beneficial blood lipid profile. Pflugers Arch 2007, 454: 971-6.
-
(2007)
Pflugers Arch
, vol.454
, pp. 971-976
-
-
Wang, P.1
van Greevenbroek, M.M.2
Bouwman, F.G.3
-
48
-
-
34547672910
-
Increased plasma visfatin concentrations in women with polycystic ovary syndrome
-
Chan TF, Chen YL, Chen HH, Lee CH, Jong SB, Tsai EM. Increased plasma visfatin concentrations in women with polycystic ovary syndrome. Fertil Steril 2007, 88: 401-5.
-
(2007)
Fertil Steril
, vol.88
, pp. 401-405
-
-
Chan, T.F.1
Chen, Y.L.2
Chen, H.H.3
Lee, C.H.4
Jong, S.B.5
Tsai, E.M.6
-
49
-
-
34447336403
-
Serum visfatin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome
-
Kowalska I, Straczkowski M, Nikolajuk A, et al. Serum visfatin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome. Hum Reprod 2007, 22: 1824-9.
-
(2007)
Hum Reprod
, vol.22
, pp. 1824-1829
-
-
Kowalska, I.1
Straczkowski, M.2
Nikolajuk, A.3
-
50
-
-
26244450785
-
Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease
-
Meyer C, McGrath BP, Teede HJ. Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease. J Clin Endocrinol Metab 2005, 90: 5711-6.
-
(2005)
J Clin Endocrinol Metab
, vol.90
, pp. 5711-5716
-
-
Meyer, C.1
McGrath, B.P.2
Teede, H.J.3
-
51
-
-
8744260883
-
Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome
-
Talbott EO, Zborowski JV, Rager JR, Boudreaux MY, Edmundowicz DA, Guzick DS. Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004, 89: 5454-61.
-
(2004)
J Clin Endocrinol Metab
, vol.89
, pp. 5454-5461
-
-
Talbott, E.O.1
Zborowski, J.V.2
Rager, J.R.3
Boudreaux, M.Y.4
Edmundowicz, D.A.5
Guzick, D.S.6
-
52
-
-
0033767890
-
Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women
-
Talbott EO, Guzick DS, Sutton-Tyrrell K, et al. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol 2000, 20: 2414-21.
-
(2000)
Arterioscler Thromb Vasc Biol
, vol.20
, pp. 2414-2421
-
-
Talbott, E.O.1
Guzick, D.S.2
Sutton-Tyrrell, K.3
-
53
-
-
0027080247
-
Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women
-
Dahlgren E, Janson PO, Johansson S, Lapidus L, Odén A. Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women. Acta Obstet Gynecol Scand 1992, 71: 599-604.
-
(1992)
Acta Obstet Gynecol Scand
, vol.71
, pp. 599-604
-
-
Dahlgren, E.1
Janson, P.O.2
Johansson, S.3
Lapidus, L.4
Odén, A.5
-
54
-
-
0033851421
-
Long-term consequences of polycystic ovary syndrome: Results of a 31 year follow-up study
-
Wild S, Pierpoint T, Jacobs H, McKeigue P. Long-term consequences of polycystic ovary syndrome: results of a 31 year follow-up study. Hum Fertil (Camb) 2000, 3: 101-5.
-
(2000)
Hum Fertil (Camb)
, vol.3
, pp. 101-105
-
-
Wild, S.1
Pierpoint, T.2
Jacobs, H.3
McKeigue, P.4
-
55
-
-
0034078044
-
Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: A retrospective cohort study
-
Wild S, Pierpoint T, McKeigue P, Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol (Oxf) 2000, 52: 595-600.
-
(2000)
Clin Endocrinol (Oxf)
, vol.52
, pp. 595-600
-
-
Wild, S.1
Pierpoint, T.2
McKeigue, P.3
Jacobs, H.4
-
56
-
-
2042548063
-
Mortality of women with polycystic ovary syndrome at long-term follow-up
-
Pierpoint T, McKeigue PM, Isaacs AJ, Wild SH, Jacobs HS. Mortality of women with polycystic ovary syndrome at long-term follow-up. J Clin Epidemiol 1998, 51: 581-6.
-
(1998)
J Clin Epidemiol
, vol.51
, pp. 581-586
-
-
Pierpoint, T.1
McKeigue, P.M.2
Isaacs, A.J.3
Wild, S.H.4
Jacobs, H.S.5
-
57
-
-
33745726758
-
Association of dehydroepiandrosterone-sulfate with endothelial function in young women with polycystic ovary syndrome
-
Dagre A, Lekakis J, Mihas C, et al. Association of dehydroepiandrosterone-sulfate with endothelial function in young women with polycystic ovary syndrome, Eur J Endocrinol 2006, 154: 883-90.
-
(2006)
Eur J Endocrinol
, vol.154
, pp. 883-890
-
-
Dagre, A.1
Lekakis, J.2
Mihas, C.3
-
58
-
-
41749103363
-
Serum concentrations of atherogenic proteins Neutrophil gelatinase-associated lipocalin and its complex with Matrix Metalloproteinase-9 are significantly lower in women with Polycystic Ovary Syndrome: Hint of a protective mechanism?
-
Diamanti-Kandarakis E, Livadas S, Kandarakis S, Margeli A, Papassotiriou I. Serum concentrations of atherogenic proteins Neutrophil gelatinase-associated lipocalin and its complex with Matrix Metalloproteinase-9 are significantly lower in women with Polycystic Ovary Syndrome: Hint of a protective mechanism? Eur J Endocrinol 2008, 158: 525-31.
-
(2008)
Eur J Endocrinol
, vol.158
, pp. 525-531
-
-
Diamanti-Kandarakis, E.1
Livadas, S.2
Kandarakis, S.3
Margeli, A.4
Papassotiriou, I.5
-
59
-
-
0031957333
-
Therapeutic effects of metformin on insulin resistance and hyper-androgenism in polycystic ovary syndrome
-
Diamanti-Kandarakis E, Kouli C, Tsianateli T, Bergiele A. Therapeutic effects of metformin on insulin resistance and hyper-androgenism in polycystic ovary syndrome. Eur J Endocrinol 1998, 138: 269-74.
-
(1998)
Eur J Endocrinol
, vol.138
, pp. 269-274
-
-
Diamanti-Kandarakis, E.1
Kouli, C.2
Tsianateli, T.3
Bergiele, A.4
-
60
-
-
33746233401
-
The new adipose tissue and adipocytokines
-
Bulcão C, Ferreira SR, Giuffrida FM, Ribeiro-Filho FF. The new adipose tissue and adipocytokines. Curr Diabetes Rev 2006, 2: 19-28.
-
(2006)
Curr Diabetes Rev
, vol.2
, pp. 19-28
-
-
Bulcão, C.1
Ferreira, S.R.2
Giuffrida, F.M.3
Ribeiro-Filho, F.F.4
-
61
-
-
0031456016
-
Insulin resistance and the polycystic ovary syndrome: Mechanism and implications for pathogenesis
-
Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997, 18: 774-800.
-
(1997)
Endocr Rev
, vol.18
, pp. 774-800
-
-
Dunaif, A.1
-
62
-
-
0030855145
-
Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome
-
Ehrmann DA, Schneider DJ, Sobel BE, et al. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997, 82: 2108-16.
-
(1997)
J Clin Endocrinol Metab
, vol.82
, pp. 2108-2116
-
-
Ehrmann, D.A.1
Schneider, D.J.2
Sobel, B.E.3
-
63
-
-
0038508940
-
Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome
-
Romualdi D, Guido M, Ciampelli M, Giuliani M, Leoni F, Perri C, Lanzone A. Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome. Hum Reprod 2003, 18: 1210-8.
-
(2003)
Hum Reprod
, vol.18
, pp. 1210-1218
-
-
Romualdi, D.1
Guido, M.2
Ciampelli, M.3
Giuliani, M.4
Leoni, F.5
Perri, C.6
Lanzone, A.7
-
64
-
-
33749035259
-
Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: A randomized placebo-controlled study
-
Rautio K, Tapanainen JS, Ruokonen A, Morin-Papunen LC. Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: a randomized placebo-controlled study. Hum Reprod 2006, 21: 1400-7.
-
(2006)
Hum Reprod
, vol.21
, pp. 1400-1407
-
-
Rautio, K.1
Tapanainen, J.S.2
Ruokonen, A.3
Morin-Papunen, L.C.4
-
65
-
-
18744362198
-
Homocysteine levels in women with polycystic ovary syndrome treated with metformin versus rosiglitazone: A randomized study
-
Kilicdag EB, Bagis T, Zeyneloglu HB, et al. Homocysteine levels in women with polycystic ovary syndrome treated with metformin versus rosiglitazone: a randomized study. Hum Reprod 2005, 20: 894-9.
-
(2005)
Hum Reprod
, vol.20
, pp. 894-899
-
-
Kilicdag, E.B.1
Bagis, T.2
Zeyneloglu, H.B.3
-
66
-
-
35448981431
-
The effect of rosiglitazone on plasma adiponectin and resistin levels in obese PCO woman-preliminary report
-
Jakubowska J, Bohdanowicz-Pawlak A, Milewicz A. The effect of rosiglitazone on plasma adiponectin and resistin levels in obese PCO woman-preliminary report. Przegl Lek 2007, 64: 70-3.
-
(2007)
Przegl Lek
, vol.64
, pp. 70-73
-
-
Jakubowska, J.1
Bohdanowicz-Pawlak, A.2
Milewicz, A.3
-
67
-
-
28544441286
-
The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome
-
Yilmaz M, Bukan N, Ayvaz G, et al. The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome. Hum Reprod 2005, 20: 3333-40.
-
(2005)
Hum Reprod
, vol.20
, pp. 3333-3340
-
-
Yilmaz, M.1
Bukan, N.2
Ayvaz, G.3
-
68
-
-
34249665044
-
Effect of 6-month treatment with oral antiandrogen alone and in combination with insulin sensitizers on body composition, hormonal and metabolic parameters in women with polycystic ovary syndrome (PCOS) in order to determine therapeutic strategy
-
Orbetsova M, Kamenov Z, Kolarov G, et al. Effect of 6-month treatment with oral antiandrogen alone and in combination with insulin sensitizers on body composition, hormonal and metabolic parameters in women with polycystic ovary syndrome (PCOS) in order to determine therapeutic strategy. Akush Ginekol (Sofiia) 2006, 45: 16-28.
-
(2006)
Akush Ginekol (Sofiia)
, vol.45
, pp. 16-28
-
-
Orbetsova, M.1
Kamenov, Z.2
Kolarov, G.3
-
69
-
-
23844436916
-
Metformin and weight loss in obese women with polycystic ovary syndrome: Comparison of doses
-
Harborne LR, Sattar N, Norman JE, Fleming R. Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses. J Clin Endocrinol Metab 2005, 90: 4593-8.
-
(2005)
J Clin Endocrinol Metab
, vol.90
, pp. 4593-4598
-
-
Harborne, L.R.1
Sattar, N.2
Norman, J.E.3
Fleming, R.4
-
70
-
-
33846875851
-
Cooperative Multicenter Reproductive Medicine Network. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome
-
Legro RS, Barnhart HX, Schlaff WD, et al; Cooperative Multicenter Reproductive Medicine Network. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med 2007, 356: 551-66.
-
(2007)
N Engl J Med
, vol.356
, pp. 551-566
-
-
Legro, R.S.1
Barnhart, H.X.2
Schlaff, W.D.3
-
71
-
-
29144477303
-
Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study
-
Tang T, Glanville J, Hayden CJ, White D, Barth JH, balen AH. Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study. Hum Reprod 2006, 21: 80-9.
-
(2006)
Hum Reprod
, vol.21
, pp. 80-89
-
-
Tang, T.1
Glanville, J.2
Hayden, C.J.3
White, D.4
Barth, J.H.5
balen, A.H.6
-
72
-
-
33745512819
-
The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome - a randomised, double-blind, placebo-controlled trial
-
Lord J, Thomas R, Fox B, Acharya U, Wilkin T. The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome - a randomised, double-blind, placebo-controlled trial. Br J Obstet Gynaecol 2006, 113: 817-24.
-
(2006)
Br J Obstet Gynaecol
, vol.113
, pp. 817-824
-
-
Lord, J.1
Thomas, R.2
Fox, B.3
Acharya, U.4
Wilkin, T.5
-
73
-
-
34347362939
-
Metformin and glitazones: Do they really help PCOS patients?
-
Pillai A, Bang H, Green C. Metformin and glitazones: do they really help PCOS patients? J Fam Pract 2007, 56: 444-53.
-
(2007)
J Fam Pract
, vol.56
, pp. 444-453
-
-
Pillai, A.1
Bang, H.2
Green, C.3
-
74
-
-
5144220551
-
Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity
-
Baillargeon JP, Jakubowicz DJ, Iuorno MJ, Jakubowicz S, Nestler JE. Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertil Steril 2004, 82: 893-902.
-
(2004)
Fertil Steril
, vol.82
, pp. 893-902
-
-
Baillargeon, J.P.1
Jakubowicz, D.J.2
Iuorno, M.J.3
Jakubowicz, S.4
Nestler, J.E.5
-
75
-
-
15944390236
-
Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome
-
Ortega-González C, Luna S, Hernández L, et al. Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005, 90: 1360-5.
-
(2005)
J Clin Endocrinol Metab
, vol.90
, pp. 1360-1365
-
-
Ortega-González, C.1
Luna, S.2
Hernández, L.3
-
76
-
-
85036842599
-
-
Legro RS, Zaino RJ, Demers LM, Kunselman AR, Gnatuk CL, et al. The effects of metformin and rosiglitazone, alone and in combination, on the ovary and endometrium in polycystic ovary syndrome. Am J Obstet Gynecol 2007, 19: 402.e1-11.
-
Legro RS, Zaino RJ, Demers LM, Kunselman AR, Gnatuk CL, et al. The effects of metformin and rosiglitazone, alone and in combination, on the ovary and endometrium in polycystic ovary syndrome. Am J Obstet Gynecol 2007, 19: 402.e1-11.
-
-
-
-
77
-
-
0028315971
-
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy
-
Velazquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 1994, 43: 647-54.
-
(1994)
Metabolism
, vol.43
, pp. 647-654
-
-
Velazquez, E.M.1
Mendoza, S.2
Hamer, T.3
Sosa, F.4
Glueck, C.J.5
-
78
-
-
0034458234
-
Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: A randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation
-
Moghetti P, Castello R, Negri C, et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 2000, 85: 139-46.
-
(2000)
J Clin Endocrinol Metab
, vol.85
, pp. 139-146
-
-
Moghetti, P.1
Castello, R.2
Negri, C.3
-
79
-
-
14644406278
-
Effects of metformin and ethinyl estradiol-cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome
-
Rautio K, Tapanainen JS, Ruokonen A, Morin-Papunen LC. Effects of metformin and ethinyl estradiol-cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome. Eur J Endocrinol 2005, 152: 269-75.
-
(2005)
Eur J Endocrinol
, vol.152
, pp. 269-275
-
-
Rautio, K.1
Tapanainen, J.S.2
Ruokonen, A.3
Morin-Papunen, L.C.4
-
80
-
-
34547406316
-
Metformin administration improves leukocyte count in women with polycystic ovary syndrome: A 6-month prospective study
-
Orio F, Manguso F, Di Biase S, et al. Metformin administration improves leukocyte count in women with polycystic ovary syndrome: a 6-month prospective study. Eur J Endocrinol 2007, 157: 69-73.
-
(2007)
Eur J Endocrinol
, vol.157
, pp. 69-73
-
-
Orio, F.1
Manguso, F.2
Di Biase, S.3
-
81
-
-
34447127552
-
Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome
-
Luque-Ramírez M, Alvarez-Blasco F, Botella-Carretero JI, Martínez-Bermejo E, Lasunción MA, Escobar-Morreale HF. Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome. J Clin Endocrinol Metab 2007, 92: 2453-61.
-
(2007)
J Clin Endocrinol Metab
, vol.92
, pp. 2453-2461
-
-
Luque-Ramírez, M.1
Alvarez-Blasco, F.2
Botella-Carretero, J.I.3
Martínez-Bermejo, E.4
Lasunción, M.A.5
Escobar-Morreale, H.F.6
-
82
-
-
36249013118
-
The effects of metformin on metabolic and cardiovascular risk factors in nonobese women with polycystic ovary syndrome
-
Sahin Y, Unluhizarci K, Yilmazsoy A, Yikilmaz A, Aygen E, Kelestimur F. The effects of metformin on metabolic and cardiovascular risk factors in nonobese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2007, 67: 904-8.
-
(2007)
Clin Endocrinol (Oxf)
, vol.67
, pp. 904-908
-
-
Sahin, Y.1
Unluhizarci, K.2
Yilmazsoy, A.3
Yikilmaz, A.4
Aygen, E.5
Kelestimur, F.6
-
83
-
-
0142247208
-
Metformin in polycystic ovary syndrome: Systematic review and meta-analysis
-
Lord JM, Flight IH, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 2003, 327: 951-3.
-
(2003)
BMJ
, vol.327
, pp. 951-953
-
-
Lord, J.M.1
Flight, I.H.2
Norman, R.J.3
-
84
-
-
22844445332
-
Effect of rosiglitazone on insulin resistance, C-reactive protein and endothelial function in non-obese young women with polycystic ovary syndrome
-
Tarkun I, Cetinarslan B, Türemen E, Sahini T, Cantürk Z, Komsuoglu B. Effect of rosiglitazone on insulin resistance, C-reactive protein and endothelial function in non-obese young women with polycystic ovary syndrome. Eur J Endocrinol 2005, 153: 115-21.
-
(2005)
Eur J Endocrinol
, vol.153
, pp. 115-121
-
-
Tarkun, I.1
Cetinarslan, B.2
Türemen, E.3
Sahini, T.4
Cantürk, Z.5
Komsuoglu, B.6
-
85
-
-
25844467331
-
Effect of rosiglitazone on endocrine, metabolism and ovulatory performance in patients with polycystic ovary syndrome and insulin resistance
-
Lv L, Liu Y. Effect of rosiglitazone on endocrine, metabolism and ovulatory performance in patients with polycystic ovary syndrome and insulin resistance. J Huazhong Univ Sci Technolog Med Sci 2004, 24: 480-2.
-
(2004)
J Huazhong Univ Sci Technolog Med Sci
, vol.24
, pp. 480-482
-
-
Lv, L.1
Liu, Y.2
-
86
-
-
0037326410
-
Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome
-
Paradisi G, Steinberg HO, Shepard MK, Hook G, Baron AD. Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003, 88: 576-80.
-
(2003)
J Clin Endocrinol Metab
, vol.88
, pp. 576-580
-
-
Paradisi, G.1
Steinberg, H.O.2
Shepard, M.K.3
Hook, G.4
Baron, A.D.5
-
87
-
-
0344442676
-
Minimal response of circulating lipids in women with polycystic ovary syndrome to improvement in insulin sensitivity with troglitazone
-
Legro RS, Azziz R, Ehrmann D, Fereshetian AG, O'Keefe M, et al. Minimal response of circulating lipids in women with polycystic ovary syndrome to improvement in insulin sensitivity with troglitazone. J Clin Endocrinol Metab 2003, 88: 5137-44.
-
(2003)
J Clin Endocrinol Metab
, vol.88
, pp. 5137-5144
-
-
Legro, R.S.1
Azziz, R.2
Ehrmann, D.3
Fereshetian, A.G.4
O'Keefe, M.5
-
88
-
-
7044253431
-
A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors
-
Chiquette E, Ramirez G, Defronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 2004, 164: 2097-104.
-
(2004)
Arch Intern Med
, vol.164
, pp. 2097-2104
-
-
Chiquette, E.1
Ramirez, G.2
Defronzo, R.3
-
89
-
-
0042624707
-
Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin
-
Glueck CJ, Moreira A, Goldenberg N, Sieve L, Wang P. Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin. Hum Reprod 2003, 18: 1618-25.
-
(2003)
Hum Reprod
, vol.18
, pp. 1618-1625
-
-
Glueck, C.J.1
Moreira, A.2
Goldenberg, N.3
Sieve, L.4
Wang, P.5
-
90
-
-
0034748334
-
Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy
-
Diamanti-Kandarakis E, Spine G, Kouli C, Migdalis I. Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy. J Clin Endocrinol Metab 2001, 86: 4666-73.
-
(2001)
J Clin Endocrinol Metab
, vol.86
, pp. 4666-4673
-
-
Diamanti-Kandarakis, E.1
Spine, G.2
Kouli, C.3
Migdalis, I.4
-
91
-
-
19744365285
-
Metformin administration improves endothelial function in women with polycystic ovary syndrome
-
Diamanti-Kandarakis E, Alexandraki K, Protogerou A, et al. Metformin administration improves endothelial function in women with polycystic ovary syndrome. Eur J Endocrinol 2005, 152: 749-56.
-
(2005)
Eur J Endocrinol
, vol.152
, pp. 749-756
-
-
Diamanti-Kandarakis, E.1
Alexandraki, K.2
Protogerou, A.3
-
92
-
-
27744599917
-
Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: Results of a 6-month study
-
Orio F Jr, Palomba S, Cascella T, et al. Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: results of a 6-month study. J Clin Endocrinol Metab 2005, 90: 6072-6.
-
(2005)
J Clin Endocrinol Metab
, vol.90
, pp. 6072-6076
-
-
Orio Jr, F.1
Palomba, S.2
Cascella, T.3
-
93
-
-
0037242513
-
Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: A randomized study
-
Morin Papunen L, Vauhkonen I, Koivunen R, Ruokonen A, Martikainen H, Tapanainen JS. Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab 2003, 88: 148-56.
-
(2003)
J Clin Endocrinol Metab
, vol.88
, pp. 148-156
-
-
Morin Papunen, L.1
Vauhkonen, I.2
Koivunen, R.3
Ruokonen, A.4
Martikainen, H.5
Tapanainen, J.S.6
-
94
-
-
33745621423
-
Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin
-
Diamanti-Kandarakis E, Paterakis T, Alexandraki K, et al. Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin. Hum Reprod 2006, 21: 1426-31.
-
(2006)
Hum Reprod
, vol.21
, pp. 1426-1431
-
-
Diamanti-Kandarakis, E.1
Paterakis, T.2
Alexandraki, K.3
-
95
-
-
2342532378
-
The polycystic ovary syndrome per se is not associated with increased chronic inflammation
-
Möhlig M, Spranger J, Osterhoff M, et al. The polycystic ovary syndrome per se is not associated with increased chronic inflammation. Eur J Endocrinol 2004, 150: 525-32.
-
(2004)
Eur J Endocrinol
, vol.150
, pp. 525-532
-
-
Möhlig, M.1
Spranger, J.2
Osterhoff, M.3
-
96
-
-
0036216342
-
Homocysteine and steroids levels in metformin treated women with polycystic ovary syndrome
-
Vrbíková J, Bicíková M, Tallová J, Hill M, Stárka L. Homocysteine and steroids levels in metformin treated women with polycystic ovary syndrome. Exp Clin Endocrinol Diabetes 2002, 110: 74-6.
-
(2002)
Exp Clin Endocrinol Diabetes
, vol.110
, pp. 74-76
-
-
Vrbíková, J.1
Bicíková, M.2
Tallová, J.3
Hill, M.4
Stárka, L.5
-
97
-
-
20744435927
-
Administration of B-group vitamins reduces circulating homocysteine in polycystic ovarian syndrome patients treated with metformin: A randomized trial
-
Kilicdag EB, Bagis T, Tarim E, et al. Administration of B-group vitamins reduces circulating homocysteine in polycystic ovarian syndrome patients treated with metformin: a randomized trial. Hum Reprod 2005, 20: 1521-8.
-
(2005)
Hum Reprod
, vol.20
, pp. 1521-1528
-
-
Kilicdag, E.B.1
Bagis, T.2
Tarim, E.3
-
98
-
-
33845217088
-
Effect of metformin administration on plasma advanced glycation end product levels in women with polycystic ovary syndrome
-
Diamanti-Kandarakis E, Alexandraki K, Piperi C, et al. Effect of metformin administration on plasma advanced glycation end product levels in women with polycystic ovary syndrome. Metabolism 2007, 56: 129-34.
-
(2007)
Metabolism
, vol.56
, pp. 129-134
-
-
Diamanti-Kandarakis, E.1
Alexandraki, K.2
Piperi, C.3
-
99
-
-
33947714047
-
Rosiglitazone treatment increases plasma levels of adiponectin and decreases levels of resistin in overweight women with PCOS: A randomized placebo-controlled study
-
Majuri A, Santaniemi M, Rautio K, et al. Rosiglitazone treatment increases plasma levels of adiponectin and decreases levels of resistin in overweight women with PCOS: a randomized placebo-controlled study. Eur J Endocrinol 2007, 156: 263-9.
-
(2007)
Eur J Endocrinol
, vol.156
, pp. 263-269
-
-
Majuri, A.1
Santaniemi, M.2
Rautio, K.3
-
100
-
-
38049177902
-
Total and high molecular weight (HMW) adiponectin levels and measures of glucose and lipid metabolism following pioglitazone treatment in a randomized placebo-controlled study in polycystic ovary syndrome
-
Glintborg D, Frystyk J, Højlund K, et al. Total and high molecular weight (HMW) adiponectin levels and measures of glucose and lipid metabolism following pioglitazone treatment in a randomized placebo-controlled study in polycystic ovary syndrome. Clin Endocrinol (Oxf) 2008, 68: 165-74.
-
(2008)
Clin Endocrinol (Oxf)
, vol.68
, pp. 165-174
-
-
Glintborg, D.1
Frystyk, J.2
Højlund, K.3
-
101
-
-
15444366255
-
Polycystic ovary syndrome
-
Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005, 352: 1223-36.
-
(2005)
N Engl J Med
, vol.352
, pp. 1223-1236
-
-
Ehrmann, D.A.1
-
102
-
-
42049083794
-
postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: Results from the National Institutes of Health-National Heart, Lung, and Blood Institute Sponsored Women's Ischemia Syndrome Evaluation
-
Shaw LJ, Bairey Merz CN, Azziz R, et al. postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: Results from the National Institutes of Health-National Heart, Lung, and Blood Institute Sponsored Women's Ischemia Syndrome Evaluation. J Clin Endocrinol Metab 2008, 93: 1276-84.
-
(2008)
J Clin Endocrinol Metab
, vol.93
, pp. 1276-1284
-
-
Shaw, L.J.1
Bairey Merz, C.N.2
Azziz, R.3
-
103
-
-
42449144300
-
Drug insight: Insulin-sensitizing drugs in the treatment of polycystic ovary syndrome - a reappraisal
-
Dunaif A. Drug insight: insulin-sensitizing drugs in the treatment of polycystic ovary syndrome - a reappraisal. Nat Clin Pract Endocrinol Metab 2008, 4: 272-83.
-
(2008)
Nat Clin Pract Endocrinol Metab
, vol.4
, pp. 272-283
-
-
Dunaif, A.1
|